Tag Archives: IPR

IP Sessions at BIO 2015: The Impact of the Inter Partes Review on (BIO)Pharma

patent

The Intellectual Property Track at the BIO International Convention was a chance for IP thought leaders in the biotech sector to discuss some of the most pressing issues impacting the industry. Let’s recap what we learned from one of the IP sessions at BIO 2015: The Impact of IPRs on (BIO)Pharma On Tuesday, patent litigation experts met to discuss inter partes review proceedings and how they are impacting biotechnology. Panelists from The Impact of IPRs Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , ,

Sen Menendez Asks SEC to Investigate IPR Abuses

Securities and Exchange Commission

New Jersey Senator Bob Menendez has asked the Securities and Exchange Commissioner (SEC) to investigate a new investment scheme designed to manipulate the stock prices of companies engaged in research and development of innovative medical therapies, to determine if the practice is illegal. As reported in this Bloomberg Business article, certain investment firms are shorting the stocks of patent-dependent life sciences companies and then using new patent litigation procedures to challenge their patents and drive Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

IP Sessions at the 2015 BIO International Convention

BIO International Convention

This year’s BIO International Convention will be host to educational sessions on the latest issues in the biotech IP sector.  The world’s largest biotechnology gathering, the convention offers attendees the chance to come together to hear, discuss, and learn about current issues affecting the biotech community. Here’s a look at the Intellectual Property Track at this year’s convention: Sessions* Intellectual Property Opening Plenary Antibody Therapeutics: May I Have Them All? The Impact of USPTO Inter Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , ,

BIO Deputy General Counsel Testifies on Patent Reform

patent

On Wednesday, March 18, BIO’s Deputy Counsel for Intellectual Property, Hans Sauer, testified in front of the U.S. Senate Judiciary Committee regarding proposed reforms to the current U.S. patent system. The hearing was a chance for the Judiciary committee to listen to experts on what should be done to halt misuse of the patent system. In his remarks, Mr. Sauer noted that while BIO appreciates efforts by Congress to curb patent troll abuses, some of Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , ,

When The Deck is Stacked Against Innovators, Everyone Loses

US_Patent_And_Trademark_Office

Yesterday, I took part in a series of successful meetings on Capitol Hill regarding the USPTO’s Inter Partes Review system (IPR). Joined by several of BIO’s member companies, we expressed our concerns with how the system is evolving into one which makes it easier for IPR challengers to win than in Federal Court. The implementation of the IPR system – developed through the 2011 America Invests Act – has unintentionally invited abuses of the USPTO Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , ,